卵巢癌患者组织中miR-135b的表达及临床意义

目的 探讨miR-135b在卵巢癌组织中的表达及意义。方法 选取2015年1月～2017年12月在解放军第一七四医院和南方医科大学深圳医院接受手术的卵巢病变患者的卵巢组织,包括28例卵巢癌组织和10例卵巢良性肿瘤组织,所有的组织均经过病理确认。运用荧光定量PCR(RT-PCR)的方法检测28例卵巢癌及10例卵巢良性肿瘤组织中miR-135b的表达水平,并分析其与卵巢癌患者年龄、组织学类型、分化程度、临床分期及淋巴结转移的关系。结果 ①28例卵巢癌组织中miR-135b 的表达量(1.90± 0.53)与10例卵巢良性肿瘤组织中miR-135b表达量(1.45±0.45)比较,差异有统计学意义(t=2.03,P<0.05); ②19例≥50岁卵巢癌患者组织中miR-135b的表达量(1.97±0.51)和20例浆液性囊腺癌组织中miR-135b的表达量(1.96±0.50)分别与9例<50岁卵巢癌患者组织中miR-135b的表达量(1.77±0.57)和8例黏液性腺癌组织中miR-135b的表达量(1.77±0.61)比较,差异均无统计学意义(t=0.743～0.846,均P<0.05)。20例中低分化组织中miR-135b的表达量(2.05±0.54),17例临床分期Ⅲ～Ⅳ期组织中miR-135b的表达量(2.10±0.46)和15例有淋巴结转移的组织中miR-135b的表达量(2.10±0.53)均分别高于8例高分化组织中miR-135b的表达量(1.55±0.25),11例临床分期I～II组织中miR-135b的表达量(1.60±0.49)和13例无淋巴结转移的组织中miR-135b的表达量(1.68±0.44)比较,差异均有统计学意义(t=5.036～7.517,均P<0.05)。结论 miR-135b在卵巢癌组织中高表达,miR-135b 的表达水平与卵巢癌的分化程度、临床分期和淋巴结转移有关。

Expression and Clinical Significance of miR-135bin Tissues of Patients with Ovarian Cancer

Objective To investigate the expression and significance of miR-135b in ovarian cancer tissues.Methods The ovarian tissue of patients with ovarian disease who underwent surgery fromthe 174th Hospital of the People's Liberation Army and the Shenzhen Hospitalof Southern Medical University from January 2015 to December 2017,including 28 ovarian cancer tissues and 10 ovarian benign tumor tissues,were selected.The tissues were confirmed by pathology.The expression levels of miR-135b in28 ovarian cancer tissues and 10 ovarian benign tumor tissues were detected byreal-time quantitative PCR(RT-PCR),and analyzed its relationship with age,histological type,degree of differentiation,clinical stage and lymph node metastasis of patients with ovarian cancer.Results ①The expression of miR-135b in 28 ovarian cancer tissues(1.90±0.53)was different from that in 10 ovarian benign tumor tissues(1.45±0.45)and they had statisticaldifference(t=2.03,P<0.05).②The expression of miR-135b in tissues of 19 patients with ovarian cancer aged ≥50 years(1.97±0.51)and the expression of miR-135b in 20 cases of serous cystadenocarcinoma tissues(1.96±0.50),compared separately with the expression of miR-135b(1.77±0.57)in 9 cases of ovarian cancer patients <50 years old and the expression of miR-135b in 8 casesof mucinous adenocarcinoma tissues(1.77±0.61),and the difference was not statistically significant(t=0.743～0.846,all P<0.05).The expression ofmiR-135b in 20 cases of moderately poorly differentiated tissues(2.05±0.54),the expression of miR-135b in the clinical stage Ⅲ～Ⅳ stage of 17 cases(2.10±0.46)and the miR-135b of 15 cases with lymph node metastasis expression level(2.10±0.53),compared separately with the expression of miR-135b in 15 well-differentiated tissues(1.55±0.25),the expression of miR-135b in 11clinically staged Ⅰ～Ⅱ tissues(1.60±0.49)and 13 tissues without lymph node metastasis miR-135b Expression level(1.68±0.44),the differences had statistically significant(t=5.036～7.517,all P<0.05).Conclusion miR-135b was highly expressed in ovarian cancer tissues.Theexpression level of miR-135b is related to the differentiation degree,clinical stage and lymph node metastasis of ovarian cancer.